Perspective Therapeutics Partners with Merck to Test Radiopharmaceutical Combo in Solid Tumors — Perspective Therapeutics, Inc.

Event summary

Perspective Therapeutics and Merck have entered a clinical collaboration to evaluate [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors.
The study will be an amendment to Perspective’s ongoing Phase 1/2a trial (NCT06710756) in non-small cell lung cancer and colorectal cancer.
Merck will supply pembrolizumab at no cost, while Perspective sponsors the study.
FAP-α is expressed in the majority of solid tumors and is associated with poor prognosis in multiple cancer types.

The big picture

This collaboration marks a strategic move for Perspective Therapeutics to combine its targeted alpha-particle therapy with Merck’s established immune checkpoint inhibitor, Keytruda. The focus on FAP-α positive solid tumors addresses a significant unmet need in oncology, particularly in cancers with poor drug penetration and immune suppression. The partnership underscores the growing trend of combining radiopharmaceuticals with immunotherapies to enhance treatment efficacy.

What we're watching

Clinical Efficacy: How the combination of [212Pb]PSV359 and Keytruda will perform in reshaping the tumor microenvironment and improving outcomes for FAP-α positive solid tumors.
Regulatory Pathway: The pace at which Perspective can advance this combination therapy through clinical trials and potentially secure regulatory approval.
Market Positioning: Whether Perspective can leverage this partnership to strengthen its position in the radiopharmaceutical space and attract additional collaborators or investors.